ArticleAnnals of neurosciences2026
A Novel Approach of Development of Robust Animal Model for Autism Spectrum Disorder.
Article in Annals of neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autism spectrum disorder (ASD) is a multifactorial neurodevelopmental disorder. Numerous environmental risk factors have been implicated in the development of ASD in human cases, suggesting that multiple aetiological agents may contribute to developing an ASD rodent model. In this study, we have investigated the pathobiological processes and outcomes in a novel rat model of ASD that incorporates clinically relevant prenatal and perinatal insults. Specifically, a gamma-aminobutyric acid modulator, valproic acid (VPA), used for perinatal insults, and postnatal hypoxia was combined to understand the critical stages of brain development in rat pups and to explore potential causal mechanisms underlying ASD. Purpose: To develop the robust animal model for ASD using VPA and hypoxia as causative agents in combination to test other efficacious medicines for ASD in future. Method: A total of 16 female and 4 male Wistar rats were selected for mating, and the delivered pups were used for the study. The pregnant female animals were divided into four groups: G1: normal control group, G2: VPA group-received a single injection of VPA intraperitoneal (i.p.) on gestational day (GD) 12.5, G3: hypoxia group, rat pups were subjected to postnatal hypoxia, G4: VPA + hypoxia group, pregnant females received VPA (i.p. on GD 12.5), followed by normal delivery, after which the pups were subjected to postnatal hypoxia. Neurodevelopmental reflex tests, neurobehavioural assessments (open field test and Morris water maze) and three-chamber social interaction tests were conducted on the rat pups. Histopathological evaluation of the pups' brains was performed. Results: The VPA, hypoxia and combined VPA + hypoxia groups exhibited significant neurobehavioural alterations, with marked delays in neurodevelopmental reflexes compared to the normal control group. Histopathological examination of the brain revealed a reduction in Purkinje cells within the Purkinje cell layer, along with extensive neuronal degeneration. The severity of both neurobehavioural deficits and histopathological abnormalities was greatest in the combined VPA + hypoxia group compared to the other experimental groups. Conclusions: These findings suggest that the combination of prenatal VPA exposure and postnatal hypoxia, representing pre- and perinatal insults, induces ASD-like conditions in rat pups that closely resemble the clinical behaviour features and redox imbalance of human ASD. Thus, this combined model could serve as a potential animal model for ASD and could be used for screening pharmacological agents aimed at treating and managing ASD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.